Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a slower intubation approach prevent dangerous blood pressure drops?

NCT ID NCT06940219

Disease control Sponsor: Leipzig University Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 26, 2026 · Last updated Aug 27, 2026 · Updated 1 time

Summary

This trial tests whether a delayed sequence induction—using ketamine and midazolam to calm the patient before intubation—can reduce severe blood pressure complications compared to the standard rapid sequence induction. It enrolls 200 critically ill adults needing emergency intubation in the ICU. The study also explores how to best measure these complications to guide future research.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Delayed Sequence Induction (a procedure using ketamine and midazolam to achieve dissociation before intubation)
What this could lead to
If successful, this could establish a safer way to intubate critically ill patients, potentially reducing dangerous drops in blood pressure and improving outcomes.
What could go wrong
This is a feasibility trial with 200 patients, so results may not be conclusive. The procedure itself carries risks, including apnea and hemodynamic instability.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients 18 years or older in need of emergency endotracheal intubation in the following 60 minutes. * The planned operateur routinely performs endotracheal intubation in critically ill patients. Exclusion Criteria: * Endotracheal Intubation performed during cardiopulmonary resuscitation or during "unstable ROSC", defined as Norepinephrine or Epinephrine dose \> 0,5 µg/kgKG/min after return of spontaneous circulation. * Participation in the study is not warranted because of increased risk for the patient or otherwise not justifiable (e.g. active oral bleeding). * Known allergy against Ketamine, Esketamine, Midazolam or Rocuronium. * Known contraindication against Ketamine, Esketamine Midazolam or Rocuronium. * Known or anticipated difficult airway with indication for awake fiberoptic intubation. * Women with known pregnancy or breastfeeding.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Intubation in intensive care units are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Intubation in intensive care units

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Interdisciplinary Medical ICU, Leipzig Medical University Center

    RECRUITING

    Leipzig, Saxony, 04317, Germany